What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 24% in the afternoon session after U.S. Food ...

HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...

The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.

We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

New service will enable blood testing for hormone levels, cardiac risk, thyroid function, and more using a blood lancet.

This is the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences.

Hims & Hers, a health and wellness platform, is set to introduce at-home lab testing capabilities through the acquisition of ...

Hims & Hers' acquisition of Trybe Labs broadens its treatment range and enhances its competitive edge through increased data ...

Hims & Hers bought an at-home lab test­ing com­pa­ny as it branch­es out in­to oth­er clin­i­cal ar­eas be­yond its re­cent ...

Hims & Hers Health shares jumped some 20% to a record high on Wednesday following the announcement that it acquired lab ...

Shares of Hims & Hers Health Inc ( HIMS 17.50%) are flying higher on Wednesday. The company's stock gained 21.7% as of 2:00 p ...